A Phase 2 interventional study of Tegoprazan 50 mg Triple Therapy and Tegoprazan 100 mg Triple Therapy in Helicobacter Pylori Infection, sponsored by HK inno.N Corporation. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-06.
Sponsored by HK inno.N Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This exploratory study is designed to compare safety and efficacy between a Tegoprazan dose-specific standard triple therapy and Lansoprazole standard triple therapy in H. pylori positive patients.
A Randomized, Double-Blind, Active-controlled, Multicenter, Therapeutic Exploratory Study to to Evaluate the Safety and Efficacy of a Standard Triple Therapy with Tegoprazan and Lansoprazole standard triple therapy in H. pylori Positive Patients, twice a day for 14 days.
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
Drug: Tegoprazan 50 mg Triple Therapy
Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
Drug: Tegoprazan 100 mg Triple Therapy
Lansoprazolee/Clarithromycin/ Amoxicillin BID peroral, 14 days
Drug: Lansoprazole Triple Therapy
Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days
H. pylori eradication rate
Assess H. pylori eradication rate by UBT
Time frame: 42 days
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Dec 2024, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan